Compare Booking Holdings Inc (BKNG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Booking Holdings Inc trades at $178.55 (market cap $135.49B), while State Street SPDR S&P Biotech ETF trades at $153.26. The key difference: Booking Holdings Inc pays a 0.92% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Booking Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BKNG | XBI | |
|---|---|---|
Market Cap | $135.49B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $231.02 | $164.28 |
52-Week Low | $154.13 | $85.16 |
Enterprise Value | $138.41B | — |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booking Holdings (BKNG) trades at $175.80, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a 22.23% net income margin and consistent revenue growth. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss, while analyst consensus remains strongly bullish with a $220.88 price target. The company maintains robust cash flow from operations at $9.41B for 2025 and continues to innovate in travel services, as highlighted by recent OpenTable initiatives.
The outlook for BKNG is positive based on solid profitability and growth prospects, though risks include high debt levels with a 64.02% debt-to-asset ratio and competitive pressures. Investment opportunity lies in its dominant market position and earnings potential, but investors should monitor execution risks and macroeconomic factors affecting travel demand.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
